NCT04985357 2024-11-25Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsTravera IncWithdrawn
NCT04129320 2022-02-08Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckMacroGenicsPhase 2/3 Withdrawn